A detailed history of Van Hulzen Asset Management, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Van Hulzen Asset Management, LLC holds 5,000 shares of ITCI stock, worth $416,750. This represents 0.03% of its overall portfolio holdings.

Number of Shares
5,000
Previous 5,300 5.66%
Holding current value
$416,750
Previous $363,000 0.83%
% of portfolio
0.03%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$67.99 - $80.84 $20,397 - $24,252
-300 Reduced 5.66%
5,000 $366,000
Q1 2024

May 06, 2024

SELL
$64.37 - $75.65 $25,748 - $30,260
-400 Reduced 7.02%
5,300 $367,000
Q4 2023

Feb 07, 2024

SELL
$46.37 - $73.65 $13,911 - $22,095
-300 Reduced 5.0%
5,700 $408,000
Q2 2023

Aug 03, 2023

SELL
$54.67 - $66.44 $21,868 - $26,576
-400 Reduced 6.25%
6,000 $380,000
Q2 2022

Aug 04, 2022

SELL
$43.0 - $65.64 $8,600 - $13,128
-200 Reduced 3.03%
6,400 $365,000
Q1 2022

May 20, 2022

SELL
$38.74 - $62.09 $19,370 - $31,045
-500 Reduced 7.04%
6,600 $404,000
Q3 2021

Nov 12, 2021

SELL
$28.72 - $42.49 $54,568 - $80,731
-1,900 Reduced 21.11%
7,100 $265,000
Q2 2021

Aug 06, 2021

SELL
$29.3 - $44.5 $23,440 - $35,600
-800 Reduced 8.16%
9,000 $367,000
Q1 2021

May 12, 2021

SELL
$30.8 - $39.51 $36,960 - $47,412
-1,200 Reduced 10.91%
9,800 $333,000
Q4 2020

Feb 16, 2021

BUY
$23.34 - $32.22 $4,668 - $6,444
200 Added 1.85%
11,000 $350,000
Q3 2020

Nov 03, 2020

BUY
$17.61 - $31.86 $3,522 - $6,372
200 Added 1.89%
10,800 $277,000
Q2 2020

Aug 11, 2020

BUY
$14.35 - $26.64 $152,110 - $282,384
10,600 New
10,600 $272,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.87B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Van Hulzen Asset Management, LLC Portfolio

Follow Van Hulzen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Hulzen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Van Hulzen Asset Management, LLC with notifications on news.